Risk Factors of Radiation Pneumonitis

Status Recruiting

Clinical Trial Summary

A prospective observational study to evaluate clinical, dosimetrical, functional, and biological factors in predicting radiation pneumonitis.

Clinical Trial Description

We propose a prospective observational study to investigate the combinational effect of radiotherapeutic dosimetric parameters [mean lung dose & percentage of lung volume receiving at least 20Gy (V20)] and biological parameters [interleukin-6(IL6) & transforming growth factor beta (TGFB)] in predicting radiation pneumonitis, fibrosis, and change of QoL among at least fifty-three lung cancer patients. Eligibility included pathological or cytological proven small cell or non small cell lung cancer, thoracic RT planned for more than 30Gy [if fraction size >= 3Gy/fx] or 40Gy [if fraction size < 3 Gy/Fx], ECOG performance status [PS] 0-2, body weight loss [BWL] <=10% in previous 6 months, no prior thoracic RT and signed informed consent prior to study entry. Basic pre-radiotherapy information will be collected, which included BWL, ECOG PS, AJCC stage [I-IV], primary lesion site, history of smoking/coexisting lung disease/dosage of chemotherapy/surgical resection, albumin level, and pulmonary function test of FEV1/VC/DLCO(optional). Computed tomography [CT] of the whole lung in treatment position with reference mark will be done for calculation of V20 and mean lung dose. Blood test of IL6, TGFB by ELISA will be done before and after RT after storage at -80℃. Bronchial-alveolar lavage test of IL6, TGFB by ELISA will be done before and after RT if clinical available. Self-reported questionnaire [EORTC C30 & L13] will be collected before and after RT and in every follow up visits after double-checked by trained assistants. RT must be given by photon energies >=6MV. Radiation pneumonitis and fibrosis will be assessed according to common toxicity criteria 3 [CTC-3] weekly during RT and in every follow up visits. Chi-square test, logistic regression, and proportional hazard ratio method will be used to investigate whether the parameter(s) can be effective in predicting radiation related sequelae. ;

Study Design

Observational Model: Defined Population, Time Perspective: Longitudinal

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00155909
Study type	Observational
Source	National Taiwan University Hospital
Contact	Chun-Ru Chien, M.D.
Phone	886-2-23123456
Email	stwo@ha.mc.ntu.edu.tw
Status	Recruiting
Phase	N/A
Start date	July 2003
Completion date	June 2006

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02490319` - Study on the Biological Prediction Models of Radiation Pneumonitis
Recruiting	`NCT03803787` - Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients	Phase 2
Completed	`NCT03796364` - Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis	Phase 2
Not yet recruiting	`NCT04632342` - Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients	Phase 2
Recruiting	`NCT05365802` - FAPI PET for Lung Fibrosis	Early Phase 1
Completed	`NCT01754909` - Mitigation of Radiation Pneumonitis and Fibrosis	Phase 2
Recruiting	`NCT05189496` - Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis	N/A
Completed	`NCT01745484` - Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation	N/A
Enrolling by invitation	`NCT02809456` - Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients	Phase 2
Recruiting	`NCT06069115` - Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort
Completed	`NCT04863027` - Use of Dual Energy Computed Tomography in Thoracic Radiotherapy Planning.
Not yet recruiting	`NCT02296281` - Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury	Phase 2
Completed	`NCT03462524` - Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology	N/A
Recruiting	`NCT05448703` - A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis
Recruiting	`NCT06079931` - The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia	Phase 2
Recruiting	`NCT04676828` - Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer	N/A
Recruiting	`NCT02735746` - Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.